Prevention

Why?

• Insulin lispro reduces episodes of severe hypoglycaemia and hypoglycaemic coma. ^a  
• Insulin glargine reduces episodes of serious hypoglycaemia. ^a

Insulin lispro causes fewer episodes of severe hypoglycaemia than actrapid

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
type 1 diabetes mellitus a	insulin lispro	short-acting insulin (actrapid)	severe hypoglycaemia at 12 weeks	29%	38% (10% to 57%)	9 (5 to 36)
			hypoglycaemic coma at 12 weeks	8%	81% (37% to 94%)	15 (5 to 52)

Insulin glargine causes fewer episodes of serious hypoglycaemia than standard insulin

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
type 1 diabetes mellitus a	insulin glargine	human NPH insulin	serious hypoglycaemia at 28 weeks	5.6%	66% (8% to 87%)	27 (15 to 210)